快速入口

Contact us

  Address:189 Guo Shou Jing Road Zhangjiang High-Tech Park,
Pudong, Shanghai, China

  Postcode: 201203

  Telephone number:
86-21-5080-1313

  Fax number: 86-21-5080-0721

  Email:center@mail.shcnc.ac.cn 

Home>>News>>main body

LSP (Holland) investment and cooperation forum held in CNCL

时间: 2011-12-06 17:50 字号:|| 点击:

Introduced by Dr. Børge Diderichsen (Danish; member of OECD Working Party on Biotechnology and European Research Council), Life Sciences Partners (Holland) investment and cooperation forum was held in Chinese National Compound Library (CNCL) on December 6, 2011. Amongst over 20 attendants are representatives from more than a dozen local institutions such as Living Ventures (China), Shanghai Dingjia Ventures, Shanghai Pharma Engine, Shanghai Pioneer Law Office, Shanghai Zerun Biotechnology and Central Research Institute of Shanghai Pharmaceuticals Holding Co., Ltd. etc., including Dr. Weiyong Wu (General Manager of Shanghai Pharm Valley Corp.), Dr. Ronxing Gan (Director of Shanghai Clinical Research Center), Mr. Eddie Chen (Vice President and Chief Representative for Greater China, Invest Sweden), Dr. Min Cui (General Partner of Bay City Capital, USA), Mr. Weihua Song (Head of  Economic Promotion Dept., Shanghai Zhangjiang INNOPARK Administrative Committee), Mr. Lanzhong Wang (General Manager of Zhangjiang State Biotech and Pharmaceutical Industrial Base) and Dr. Guangce Jiang (the Congrong Healthcare Security Investment Trust Fund Manager). Professor Ming-Wei Wang, Director of the National Center for Drug Screening hosted the event.

Mr. Martijn Kleijwegt, managing partner and co-founder of LSP and Dr. Joep Muijrers, Partner of LSP briefly introduced LSP and the purpose of their trip. Ranked the number 1 among life science investors in Europe, LSP has significant experience and excellent track record in healthcare and biotech investing. To capture opportunities created by the rapid development in Chinese scientific innovation, biopharmaceutical investment and technology transfer, LSP intends to establish a dedicated China Fund to invest in entrepreneuric and innovation activities, by use of its rich professional expertise and vast social network.

The participants individually presented their own experience and plan in drug development, technology transfer and capital investment, followed by serious discussions on the aspects of mutual interest. During the interval, they toured the brand new facility of CNCL and were highly inspired by its grand scale and state-of-the-art setup.
 

收藏   打印   关闭 Last: Vice Minister Qian Liu and Vice Mayor Xiaoming Shen visited CNCL Next: President of Austrian Academy of Sciences visited CNCL